CSIMarket
 


Centessa Pharmaceuticals Plc  (CNTA)
Other Ticker:  
 

Cumulative Centessa Pharmaceuticals Plc's Long Term Debt to Equity for Trailing Twelve Months Period

CNTA's Long Term Debt to Equity for Trailing Twelve Months Period and Long Term Debt, Equity growth


Select the Comparisons : Select the Ratio:

CNTA Long Term Debt to Equity for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Growth -30.44 % -34.15 % -38.92 % -31.61 % -32.09 %
Y / Y Long Term Debt Growth 8.5 % 8.75 % -4.28 % -7.79 % -
Long Term Debt to Equity for Trailing Twelve Months Period 0.25 0.22 0.19 0.17 0.16
Total Ranking # 986 # 959 # 903 # 1008 # 897
Seq. Equity Growth -6.22 % -5.68 % -12.76 % -9.86 % -11.22 %
Seq. Long Term Debt Growth 0.95 % 2.37 % 2.58 % 2.35 % 1.19 %


Long Term Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to net new long-term borrowings of 0.95%, Long Term Debt to Equity for Trailing Twelve Months Period improved to 0.25, a new company high.
Long Term Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 79 other companies have achieved lower Long Term Debt to Equity for Trailing Twelve Months Period than Centessa Pharmaceuticals Plc. While total ranking remained unchanged compare to previous quarter at no. .

What is Long Term Debt to Equity Ratio?
What is CNTA selling?
Long Term Debt to Equity CNTA in the most recent quarter
Long Term Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 80
Sector # 184
S&P 500 # 1070


Long Term Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
0.25 0.15 0.04
(Sep 30 2023)   (Dec 31 2021)




Companies with similar average Long Term Debt to Equity for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to Equity for Trailing Twelve Months Period
Axsome Therapeutics Inc   0.67 
Journey Medical Corporation  0.65 
Pds Biotechnology Corp  0.63 
Royalty Pharma Plc  0.62 
Biovie Inc   0.62 
Iterum Therapeutics Plc  0.61 
Opiant Pharmaceuticals Inc   0.60 
Maravai Lifesciences Holdings Inc   0.59 
Petros Pharmaceuticals inc   0.58 
Amphastar Pharmaceuticals Inc   0.57 
Aptinyx Inc   0.54 
Emergent Biosolutions Inc   0.53 
Scpharmaceuticals Inc   0.52 
Eyenovia inc   0.51 
Horizon Therapeutics Public Limited Company  0.50 
Pfizer Inc  0.49 
Capricor Therapeutics inc   0.48 
Milestone Pharmaceuticals inc   0.46 
Syros Pharmaceuticals Inc   0.44 
Verastem inc   0.44 
Orgenesis Inc   0.44 
Harmony Biosciences Holdings inc   0.43 
Rani Therapeutics Holdings Inc   0.41 
Cumberland Pharmaceuticals Inc  0.41 
Blueprint Medicines Corporation  0.41 
Abbott Laboratories  0.40 
Rockwell Medical inc   0.40 
Mustang Bio inc   0.40 
Dynavax Technologies Corporation  0.39 
Johnson and Johnson  0.38 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com